SCHEDULE: Glazer Capital Exits Amicus Therapeutics Position

Glazer Capital, LLC and Paul J. Glazer have filed an exit notice confirming they no longer beneficially own more than 5% of Amicus Therapeutics, Inc. common stock.

Summary

• Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G amendment indicating they have ceased to be beneficial owners of more than 5% of Amicus Therapeutics, Inc. common stock.
• The reporting persons now report 0 shares beneficially owned, representing 0% of the class.
• The event triggering this filing occurred on April 24, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure confirming the cessation of a significant shareholding position.

Positives

• The filing confirms a clean exit from the position, removing potential overhang associated with a large institutional holder selling off shares.

Negatives

• The departure of an institutional investor like Glazer Capital may be perceived as a lack of confidence in the near-term performance of the issuer.

Risks

• None identified in this specific filing.

Future Outlook

No forward-looking guidance provided as this is a notice of divestment.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is common as funds rebalance portfolios or rotate out of specific therapeutic areas; this filing reflects a standard regulatory disclosure of a position exit.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for institutional investors (13G) when crossing the 5% ownership threshold in either direction.

Stakeholder Impact

• Shareholders may note the removal of a significant institutional holder, which can impact liquidity or market sentiment.

Next Steps

• None required for the reporting persons regarding this issuer.

Key Dates

Keywords

Amicus Therapeutics, Glazer Capital, Schedule 13G, Institutional Ownership, Divestment, Biotech